FDA approves MSD’s KEYTRUDA as first-line MPM treatment
The US FDA has granted approval for MSD’s KEYTRUDA regimen as a first-line treatment for malignant pleural mesothelioma (MPM).
The US FDA has granted approval for MSD’s KEYTRUDA regimen as a first-line treatment for malignant pleural mesothelioma (MPM).
What's Your Reaction?
